Incyte to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on July 31
More News related to INCY
- Notable Analyst Rating Changes 8/29: CBT, NZ, INCY Upgraded; WBD, ENER, WSM Downgraded
- ARGUS Upgrades Incyte Corp. (INCY) to Buy
- Incyte to Present at Upcoming Investor Conferences
- Citi Initiates Coverage of Incyte Corporation (INCY) with a Buy
- Atticus Capital 13F Shows New Stakes in Chesapeake (CHK), Focus Media (FMCN), Google (GOOG), Peabody (BTU); Lowers Stakes in Freeport-McMoRan (FCX), MasterCard (MA), NYSE Euronext (NYX)
More News related to Press Releases
- Caris & Co Initiates Coverage on C. R. Bard (BCR) with an Above Average
- Caris & Co Initiates Coverage on Cinemark (CNK)
- Caris & Co Initiates Coverage on Medtronic (MDT) with an Average Rating
- Caris & Co Initiates Coverage on St. Jude (STJ)
- Sterne Agee Initiates Coverage Engineering & Heavy Construction Stocks CBI, FLR, JEC, SGR and FWLT
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2008 financial results conference call for 8:30 a.m. ET on Thursday, July 31, 2008. The schedules for the press release and conference call are as follows:
-- Q2 2008 Press Release: July 31, 2008 at 7:00 a.m. ET
-- Q2 2008 Conference Call: July 31, 2008 at 8:30 a.m. ET
-- Domestic Dial In Number: 877-407-8037
-- International Dial In Number: 201-689-8037
-- Conference ID # 291287
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and dial-in number for international callers is 201-612-7415. To access the replay you will need the conference account number 278 and the ID number 291287.
The conference call will also be webcast live on CCBN and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. Incyte's pipeline includes multiple compounds in Phase I and Phase II development for oncology, inflammation and diabetes. For additional information on Incyte, visit the Company's web site at www.incyte.com.
Source: Incyte Corporation
Related Categories
Press ReleasesStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
